Obesity, kidney dysfunction and hypertension: mechanistic links
JE Hall, JM do Carmo, AA da Silva, Z Wang… - Nature reviews …, 2019 - nature.com
Excessive adiposity raises blood pressure and accounts for 65–75% of primary
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …
Treatment of resistant and refractory hypertension
MC Acelajado, ZH Hughes, S Oparil… - Circulation …, 2019 - Am Heart Assoc
Resistant hypertension (RHTN) is defined as uncontrolled blood pressure despite the use
of≥ 3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like …
of≥ 3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like …
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double …
R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo… - The Lancet, 2019 - thelancet.com
Background Spironolactone is effective at reducing blood pressure in patients with
uncontrolled resistant hypertension. However, the use of spironolactone in patients with …
uncontrolled resistant hypertension. However, the use of spironolactone in patients with …
Prevalence of apparent treatment-resistant hypertension in the United States: comparison of the 2008 and 2018 American Heart Association scientific statements on …
In 2018, the American Heart Association published a Scientific Statement on resistant
hypertension. We compared the prevalence of apparent treatment-resistant hypertension …
hypertension. We compared the prevalence of apparent treatment-resistant hypertension …
[HTML][HTML] Redefining diuretics use in hypertension: why select a thiazide-like diuretic?
M Burnier, G Bakris, B Williams - Journal of hypertension, 2019 - journals.lww.com
Diuretics are listed in hypertension guidelines as one of three equally weighted first-line
treatment options. In order to differentiate between antihypertensives, a lot of discussion has …
treatment options. In order to differentiate between antihypertensives, a lot of discussion has …
Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with
kidney disease, particularly in those in whom diabetes and heart failure are present or are …
kidney disease, particularly in those in whom diabetes and heart failure are present or are …
Resistant hypertension: novel insights
G Lamirault, M Artifoni, M Daniel… - Current hypertension …, 2019 - hal.science
Hypertension is the most common chronic disease and the leading risk factor for disability
and premature deaths in the world, accounting for more than 9 million deaths annually …
and premature deaths in the world, accounting for more than 9 million deaths annually …
[HTML][HTML] 2019 Chinese guideline for the management of hypertension in the elderly
Q Hua, L Fan, J Li - Journal of geriatric cardiology: JGC, 2019 - ncbi.nlm.nih.gov
2019 Chinese guideline for the management of hypertension in the elderly - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome
Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder,
caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11 β-HSD2) …
caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11 β-HSD2) …
Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men's issue?
AA Manolis, TA Manolis, H Melita… - Current hypertension …, 2019 - Springer
Abstract Purpose of Review To review comparative efficacy and tolerability data between the
two main mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, in …
two main mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, in …